Lung Cancer

The MET gene can undergo fusion in addition to mutations such as amplification/expression and exon 14 jumps. This probe detects the MET-PTPRZ1 fusion gene.

Central Nervous System Tumors

MET genes can undergo MET-PTPRZ1 fusion in addition to mutations such as amplification/expression and exon 14 jumps. All three MET gene-associated molecular events are concentrated in inspired glioblastoma, suggesting that they may promote progression of low-grade gliomas to inspired glioblastoma. A targeted drug against the MET-PTPRZ1 fusion, burretinib, is undergoing phase I clinical trials. If successful, it could provide an effective targeted therapy for approximately 14% of secondary glioblastomas in the clinic.